Vaccines
A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.
Belgium researchers compared the Moderna and Pfizer-BioNTech COVID-19 vaccines and found that the Moderna jabs generated twice the antibodies than the Pfizer-BioNTech vaccine.
Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.
Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
As many children go back to school, new waves of COVID-19 cases continue to surge. More data keeps coming in on potential vaccine risks and how they measure up against the risk of the disease. Here’s a look.
Merck has announced its vaxneuvance for pneumococcal disease in infants and has met key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
PRESS RELEASES